nach oben

Osteoporosis International

Erschienen in:

01.06.2010 | Review

Microarchitecture in focus

verfasst von: R. Rizzoli

Erschienen in: Osteoporosis International | Sonderheft 2/2010

Einloggen, um Zugang zu erhalten

Excerpt

Osteoporosis is a complex disease characterized by a decrease in bone mass and alterations of bone quality leading to increased bone fragility and fracture risk. The increasing worldwide incidence of osteoporosis requires the use of effective treatments. The aim of antiosteoporotic treatments is to improve bone strength and thus to decrease the risk of fracture [1, 2]. Bone quality includes several aspects of bone composition and structure, including microstructure, bone turnover, the degree of mineralization, and the extent of microdamage. Bone quality is being given increased importance as recent observations demonstrate that traditional measures of bone density do not always predict fracture risk reliably [3]. …

Ammann P, Rizzoli R, Bonjour JP (1998) Preclinical evaluation of new therapeutic agents for osteoporosis. In: Meunier PJ (ed) Osteoporosis: diagnosis and management. Dunitz, London, pp 257–273

Rizzoli R, Bruyere O, Cannata-Andia JB, Devogelaer JP, Lyritis G, Ringe JD, Vellas B, Reginster JY (2009) Management of osteoporosis in the elderly. Curr Med Res Opin 25:2373–2387

Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604CrossRefPubMed

Russell RGG, Espina B, Hulley Ph (2006) Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 18(1):S3–S11CrossRefPubMed

Kalpakcioglu BB, Morshed S, Engelke K, Genant HK (2008) Advanced imaging of bone macrostructure and microstructure in bone fragility and fracture repair. J Bone Joint Surg Am 90(Suppl 1):68–78CrossRefPubMed

Genant HK, Engelke K, Prevrhal S (2008) Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) 47(suppl 4):iv9–iv16CrossRef

Bouxsein ML (2009) Measuring bone quality and bone strength. In: Innovation in skeletal medicine. Elsevier-Masson, pp 85–98

Bouxsein ML (2008) Technology insight: noninvasive assessment of bone strength in osteoporosis. Nat Clin Pract Rheumatol 4(6):310–318CrossRefPubMed

Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMed

10.

Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34:195–202CrossRefPubMed

11.

Arlot ME, Jiang Y, Genant HK et al (2008) Histomorphometric and μCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215–222CrossRefPubMed

12.

Croucher PI, Garrahan NJ, Compston JE (1996) Assessment of cancellous bone structure: comparison of strut analysis, trabecular bone pattern factor and marrow space star volume. J Bone Miner Res 11:955–961CrossRefPubMed

13.

Brandi ML (2009) Microarchitecture, the key to bone quality. Rheumatology 48:iv3–iv8CrossRefPubMed

14.

Jårvinen TLN, Sievånen H, Jokihaara J, Einhorn TA (2005) Revival of bone strength: the bottom line. J Bone Miner Res 20:717–720CrossRefPubMed

15.

Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508–6515CrossRefPubMed

16.

Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M et al (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21:124–131CrossRefPubMed

17.

Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed

18.

Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14CrossRefPubMed

19.

Hochberg MC, Greenspan S, Wasnich RD et al (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592CrossRefPubMed

20.

Liberman UA, Weiss SR, Bröll J, the Alendronate Phase III Osteoporosis Treatment Study Group et al (1995) N Engl J Med 333:1437–1443, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisCrossRefPubMed

21.

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed

22.

Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647CrossRefPubMed

23.

Cummings SR, Karpf DB, Harris F et al (2002) Improvement in Spine Bone Density and reduction in risk of vertebral fractures during treatment antiresorptive drugs. Am J Med 112(4):281–289CrossRefPubMed

24.

Ammann P, Rizzoli R, Meyer JM et al (1996) Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int 6:219–227CrossRefPubMed

25.

Balena R, Toolan BC, Shea M et al (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primate. J Clin Invest 92:2577–86CrossRefPubMed

26.

Blake GM, Lewiecki EM, Kendler DL, Fogelman I (2007) A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10:113–119CrossRefPubMed

27.

Blake GM, Fogelman I (2007) The correction of BMD measurements for bone strontium content. J Clin Densitom 10:259–265CrossRefPubMed

28.

Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076–3081CrossRefPubMed

29.

Bruyère O, Roux C, Badurski J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23:3041–3045CrossRefPubMed

30.

Rizzoli R, Felsenberg D, Laroche M et al (2009) Superiority of strontium ranelate as compared to alendronate on microstructural determinants of bone strength at the distal tibia in women with postmenopausal osteoporosis. Ann Rheum Dis 68:669

Titel: Microarchitecture in focus
verfasst von: R. Rizzoli
Publikationsdatum: 01.06.2010
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe Sonderheft 2/2010
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1242-1

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Microarchitecture in focus

Excerpt

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2010

Strontium ranelate: an effective solution for diverse fracture risks

Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture

Addressing the age-related needs of osteoporotic patients with strontium ranelate

Fracture prevention in osteoporosis: assessing risks, providing solutions

Development and use of FRAX® in osteoporosis

Osteoporosis: disease severity and consequent fracture management

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie